4SC AG Kiemelkedően
Mi az 4SC AG Kiemelkedően?
A Kiemelkedően az 4SC AG - 50.570M
Mi a Kiemelkedően meghatározása?
A fennálló részvények egy olyan vállalat vagy pénzügyi eszköz részvényei, amelyeket a befektetők engedélyeztek, bocsátottak ki és vásároltak meg.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Kiemelkedően a Health Care szektor a XETRA-on cégekben a 4SC AG -hoz képest
Mit csinál 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
kiemelkedően -hoz hasonló cégek 4SC AG
- Renewable Inc nak Kiemelkedően 50.507M van
- Gespeg Resources nak Kiemelkedően 50.509M van
- Cosmo Metals nak Kiemelkedően 50.510M van
- Cooper Tire & Rubber Co nak Kiemelkedően 50.524M van
- KFG Resources nak Kiemelkedően 50.540M van
- Cohen & Steers nak Kiemelkedően 50.551M van
- 4SC AG nak Kiemelkedően 50.570M van
- Tata Investment nak Kiemelkedően 50.595M van
- Tata Investment nak Kiemelkedően 50.595M van
- abrdn Healthcare Investors nak Kiemelkedően 50.625M van
- HeadHunter PLC nak Kiemelkedően 50.636M van
- Onxeo SA nak Kiemelkedően 50.647M van
- Forestar Inc nak Kiemelkedően 50.654M van